Rakovina Therapeutics (RKV.V) - Capital Market Series w/ Jeffrey Bacha - CEO

In the eleventh episode of NewGen Mindset's "Capital Market Series," Nic and Dan sit down with Jeffrey Bacha from Rakovina Therapeutics. We first begin by getting to better know Jeffrey's past and what led his profession to being a part of Rokavina. His passion and desire to be part of solutions to improve and optimize lives is truly respectable, and it shows with the endeavors he seeks to be a part off. We then dig into the purpose of Rokavina where their work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ platform they have incorported into their processes to optimize time and costs. This is a story where we get to see how AI advances at a more optimal rate the drug development, in a sector that traditionally takes countless years. With a tight float, small market cap and vast potential in a sector worth countless billions, Rakovina is a fascinating story with with a fascinating team at the helm. Jeffrey Bacha, BSc, MBA - Executive Chairman Mr. Bacha has been involved in pharmaceutical research and corporate development for more than 25 years as a member of the executive leadership team for multiple companies. Mr. Bacha is the founder and chief executive officer of Edison Oncology Holding Corp., a private corporation which sold assets to establish Rakovina Therapeutics Inc. Prior to founding Edison Oncology, Mr. Bacha co-founded Kintara Therapeutics (NASDAQ: KTRA, formerly DelMar Pharmaceuticals) with Dr. Dennis Brown and served as Chairman and CEO during the company’s growth including the advancement of its lead product candidate to pivotal Phase III clinical trials and NASDAQ listing. Mr. Bacha was served as president and founding CFO of XBiotech, Inc. (NASDAQ: XBIT), founding CEO of Inimex Pharmaceuticals and as of Vice President, Corporate Development at Inflazyme Corp. Programs advanced by Inimex and Inflazyme have become foundational in Soligenix, Inc. (NASDAQ: SNGX) and Aquinox Pharmaceuticals (NASDAQ: AQXP). He is a member of the National Brain Tumor Society Research Roundtable and the Board of the Leukemia Lymphoma Society of Canada. Mr. Bacha currently serves as a consultant to DelMar Pharmaceuticals and Valent Technologies LLC, and as a member of the Board of Directors of Sernova Corp. (TSX-V: SVA). Prior to taking on his operating roles, Mr. Bacha served Senior Manager and Director of KPMG Health Ventures, acting as an advisor to numerous public and private life sciences companies. Mr. Bacha holds an MBA (Hons) from the Goizueta Business School at Emory University (1995) and a degree in BioPhysics from the University of California, San Diego (1991). Mr. Bacha is the inventor or co-inventor on multiple issued U.S. patents and applications, many with foreign counterparts. Rakovina Therapeutics (RKV.V) Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ platform. By using AI, we can review and optimize drug candidates at a much greater pace than ever before. The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Website: https://www.rakovinatherapeutics.com/ https://www.newgenmindset.com/ Instagram: @newgenmindsetpod X: @newgen_mindset